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EGF receptorMouse prostate membrane-associated proteins of the annexin family showed changes in SUMOylation
during androgen treatment. Among these the calcium-binding annexin A1 protein (ANXA1) was chosen
for further characterization given its role in protein secretion and cancer. SUMOylation of ANXA1 was
conﬁrmed by overexpressing SUMO-1 in LNCaP cells. Site-directed mutagenesis indicated that K257 located
in a SUMOylation consensus motif in the C-terminal calcium-binding DA3 repeat domain is SUMOylated. Mu-
tation of the N-terminal Y21 decreased markedly the SUMOylation signal while EGF stimulation increased
ANXA1 SUMOylation. A structural analysis of ANXA1 revealed that K257 is located in a hot spot where
Ca2+ and SUMO-1 bind and where a nuclear export signal and a polyubiquitination site are also present.
Also, Y21 is buried inside an α-helix structure in the Ca2+-free conformation implying that Ca2+ binding,
and the subsequent expelling of the N-terminal α-helix in a disordered conformation, is permissive for its
phosphorylation. These results show for the ﬁrst time that SUMOylation can be regulated by an external
signal (EGF) and indicate the presence of a cross-talk between the N-terminal and C-terminal domains of
ANXA1 through post-translational modiﬁcations.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license. 1. Introduction
Annexin A1 (ANXA1) is a Ca2+ and phospholipid binding protein.
It is involved in many important cellular processes, such as mem-
brane trafﬁcking, signal transduction, cellular differentiation, prolifer-
ation and cancer [1]. Most of the proteins of the annexin family are
composed of two domains, the variable N-terminal domain and a
conserved C-terminal core region consisting of four repeats (DA1 to
DA4) of approximately 70 residues [1]. The Ca2+ binding sites are
localized in the convex region of the C-terminal core and the ﬂexible
N-terminal domain, when positioned on the opposite concave side,
allows protein–protein interactions events [1]. Studies have shown
that phosphorylation, truncation or mutation of the N-terminal domainer; ANXA1, annexin A1; 1-DE,
ensional gel electrophoresis;
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nc. Open access under CC BY license. have an important impact in calciumbinding in the C-terminal core and
membrane binding/aggregation [2–5] suggesting the presence of a
cross-talk between the N-terminal domain and the C-terminal core
region.
The functions of annexins were characterized in some details in
terms of membrane or actin dynamics [6–8]. They have reported
functions in both the secretory [9,10] and the endocytic pathways
[6]. It was shown that ANXA1 is a substrate of the EGFR tyrosine
kinase [11] and is required for EGFR trafﬁcking downstream of the
substrate Hrs and the ESCRT system [12]. Several studies have also
reported the role of ANXA1 in prostate cancer. Christmas et al. [13]
have shown that the human prostate gland selectively secretes high
concentrations of ANXA1 into the seminal plasma. The expression of
ANXA1 is decreased in prostate cancer development in association
with recurrence after androgen deprivation therapy [14]. It has also
been shown that ANXA1 may have tumor suppression functions [15].
Protein activity is regulated by many reversible chemical modiﬁca-
tions including covalent modiﬁcations by small ubiquitin-related
modiﬁer protein SUMO. SUMOylation can regulate protein–protein
interactions, protein localization, function and turnover [16–18].
UBC9 catalyzes the formation of an isopeptide bond between the
C-terminus of SUMO and the amino group of the target lysine generally
within the consensus motif ψKXE/D, where ψ is a large hydrophobic
amino acid and X any amino acid [19–22]. Until recently, protein
1963D. Caron et al. / Cellular Signalling 25 (2013) 1962–1969SUMOylation has almost been solely associated with nuclear events
such as transcriptional factor modiﬁcation and nuclear protein trans-
port (for reviews [20,21,23]). It was demonstrated that protein
SUMOylation is also present in other compartments including the mi-
tochondria [24,25]. Proteins involved in membrane trafﬁcking events
were also found SUMOylated [10,22,26–29].
A role for SENP1, a deSUMOylation enzyme in the development of
prostate cancer was reported [30,31]. In a recent proteomic survey of
the mouse prostate we identiﬁed a large pool of free SUMO-1 peptides,
responsive to castration and the androgen DHT [32]. Here, a coincident
proﬁle of changes in protein SUMOylation was detectable in crude
membrane and cytosol fractions. Among the SUMOylated candidates,
we have identiﬁed, by two-dimensional electrophoresis (2-DE)
coupled with mass spectrometry, members of the annexin family. We
conﬁrmed the SUMOylation of ANXA1 in cultured LNCaP prostate
cells and have identiﬁed the major SUMOylated site in the C-terminal
DA3 domains. We also found that Y21, a target of the EGF receptor
(EGFR) [6], regulates the ANXA1 SUMOylation process.
2. Experimental procedures
2.1. Animals
Adult (12–15 week old, weight = 25–30 g) male C57BL6 mice,
supplied by Charles River Canada Inc. (St. Constant, Canada), were
maintained under standard laboratory conditions with food and water
available ad libitum except that food was removed 18 h prior to organ
collection. The work was conducted with the approval of Laval Univer-
sity Animal Care committee. Mice were assigned to 4 groups of 12 ani-
mals each. With the exception of the control group, they were
gonadectomized (GDX) via the scrotal route under isoﬂurane-induced
anesthesia 7 days prior to organ collection. Mice assigned to a control
GDX group received a single subcutaneous injection of 0.2 ml 0.4%
methyl cellulose/5% ethanol (vehicle) 24 h prior to organ collection
while experimental groups of GDXmice received a single subcutaneous
injection of DHT (5α-dihydrotestosterone at 0.1 mg/mouse, from
Steraloids, Newport, Rhode Island) 24 h and 96 h prior to organ collec-
tion. The prostate (ventral and dorsal lobes) was collected and
sub-cellular fractionation was processed immediately as previously de-
scribed [32]. The yields of the fractionswere: Crudemembrane, control:
4.9 ± 0.9, GDX: 5.8 ± 1.8, DHT 24 h: 6.3 ± 1.5 and DHT 96 h: 6.5 ±
1.1 mg protein/g prostate (n = 6). Protein contents were measured
using the Bradford micro-technique (#500-0006, Bio-Rad, Hercules,
CA) by comparison with a BSA standard and fractions were stored at
−80 °C.
2.2. Immunoblot analysis
Antibodies were obtained from various suppliers: anti-GFP
(Invitrogen Life technology, Carlsbad, CA), anti-MYC (9E10) (Santa
Cruz Biotechnology, Santa Cruz, CA), anti-β-galactosidase (Promega,
Madison, WI), anti-EGFR, anti-p-TYR (PY20) and β-tubulin (Santa
Cruz Biotechnology, Santa Cruz, CA). The anti-SUMO antibody was pro-
duced in the laboratory and its properties previously described [32].
Signals were standardized according to protein content (150 μg
protein per lane) and revealed using the appropriate horseradish
peroxidase-conjugated secondary antibody (Jackson ImmunoResearch
Laboratories, Westgrove, PA). Membranes (PVDF) were revealed
using a chemiluminescence kit (ECL, PerkinElmer life science, Boston,
MA) and exposed on a Kodak ﬁlm (X-Omat Blue XB-1, Kodak).
2.3. Two dimensional electrophoresis (2-DE)
Proteins from mouse membrane fraction were solubilized with
7 M Urea, 2 M Thiourea, 3% CHAPS, 80 mM DTT, 0.5% Bio-Lyte 3–10
with a trace of bromophenol blue. First dimensional proteinseparation was achieved by isoelectric focusing (IEF) with the Prote-
an IEF Cell system (BioRad, Hercules, CA) using 17 cm pH 3–10 gradi-
ent IPG strip. IEF were run at 250 V constant during 15 min, 5 h of
increasing voltage to get to 10,000 V and an undetermined period at
10,000 V constant to get to 30,000 V. Strips were stored at −80 °C.
IPG strips were re-equilibrated using 2% DTT and 4% iodoacetamine
with a trace of bromophenol blue. The second dimension separation
by 11% SDS-PAGE electrophoresis was performed using the Protean
Plus Dodeca cell system (BioRad, Hercules, CA). Protein visualization
was made by SYPRO Ruby protein stain (BioRad, Hercules, CA).2.4. Protein in-gel digestion
Spots matching with the immunoblot signals were extracted from
gels using an automated spot cutter (ProteomeWorks spot cutter,
BioRad, Hercules, CA) and placed in 96-well plates and then washed
with water. Tryptic digestion and mass spectrometry analyses were
performed as previously described [32].2.5. Database searching
All MS/MS samples were analyzed using Mascot (Matrix Science,
London, UK; version 2.2.0) as previously described [32]. Mascot was
set up to search the Mus musculus Uniref100 database (version 8.0,
87,442 entries) assuming that the digestion enzyme was trypsin.
Mascot was searched with a fragment ion mass tolerance of 0.50 Da
and a parent ion tolerance of 2.0 Da. An iodoacetamide derivative of
cysteine was speciﬁed as ﬁxed modiﬁcation. Oxidation of methionine
was speciﬁed as a variable modiﬁcation. Two missed cleavages were
allowed. Scaffold (version Scaffold-2-05-02, Proteome Software Inc.,
Portland, OR) was used to validate MS/MS based peptide and protein
identiﬁcations. Protein identiﬁcations were accepted if they could be
established at greater than 95.0% probability and contained at least
1 identiﬁed peptide. Protein probabilities were assigned by the
Protein Prophet algorithm. Proteins that contained similar peptides
and that could not be differentiated by MS/MS analysis alone were
grouped in order to satisfy the principles of parsimony.2.6. Cell culture
LNCaP (LNCaP.FGC, ATCC/CRL-1740) cells were maintained in RPMI
1640 medium (HyClone) containing 10% FBS, 2.05 mM L-glutamine,
1.105/0.1 mg/ml penicillin/streptomycin and cultured at 37 °C in a 5%
CO2 constant atmosphere. In some experiments (Fig. 5), cells were
grown in the absence of FBS 2 h before EGF stimulation (15 min,
15 ng/ml).2.7. Cells transfection
Cells were plated 20 h in advance at a desired conﬂuence. Cells
were washed once with the culture medium and incubated 24 h in
medium containing the plasmid:Fugene HD (Roche Diagnostics
Canada, Laval, QC) complex (ratio 2 μg DNA: 9 μl Fugene HD) prepared
according to the manufacturer's protocol. All SUMO plasmids were
co-transfected with a plasmid expressing UBC9. The non-transfected
(NT) control was realized using empty vector. A reporter vector
pCMV-β-galactosidase (pCMVβGal CLONTECH Laboratories, Mountain
View, CA) was also co-transfected to normalize transfection efﬁciency
using a β-galactosidase assay (according to themanufacturer's protocol
PROMEGA, Madison, WI). After this incubation, the medium was
changed and left for another 24 h of expression before proceeding.
Cellular lysates were solubilized in Laemmli sample buffer and boiled
for 5 min.
Fig. 1. Protein SUMOylation proﬁles in prostate fractions. Mouse membrane prostate
fractions were prepared from control, castrated (GDX) and castrated mice stimulated
with DHT for the indicated time (DHT). Proteins (80 μg) were separated by SDS-PAGE
and transferred on PVDF membrane. Immunoblots were realized using the α-SUMO-1
antibody. Protein bands having increased signal are pointed with star symbols.
Fig. 2. 2-DE SUMOylation proﬁles of mouse prostate membranes. Proteins (0.5 mg; membr
using SYPRO Ruby protein stain (upper panel). Replicated gels were submitted to the im
white arrows show the different protein spots that are increased (black) or decreased (wh
spots (annexins were identiﬁed in spot 1) of interest were excised and submitted to the m
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Total cellular RNA from mouse ﬁbroblast (MF WT) was extracted
using TRIzol Reagent (Invitrogen) according to the manufacturer's
instructions. Two microgram of total ARN was used to synthesize the
cDNA using Omniscript reverse transcriptase (Qiagen) in a volume of
20 μl. Two microliters of this cDNA was subsequently used for PCR
analysis. The pGFP-SUMO-1GG and pGFP-SUMO-1Δ plasmids, express-
ing enhanced GFP-tagged SUMO-1 coding sequence on its constitutive
active formwith a diglycine group at the end (SUMO-1GG) or an inactive
form (G96Δ) where the glycine group has been replaced by a stop
sequence (SUMO-1Δ) respectively, were realized using the complete
SUMO-1 human coding sequence ampliﬁed with SUMO-1GG forward
primer: 5′-GATCTCGAGATGTCTGACCAGGAGGC-3′; SUMO-1GG reverse
primer: 5′-GCTCTAGACTAACCCCCCGTTTGTTCCTG-3′; SUMO-1Δ for-
ward primer: 5′-GATCTCGAGATGTCTGACCAGGAGGC-3′; and SUMO-
1Δ forward reverse primer: 5′-GCTCTAGACTACGTTTGTTCCTG-3′. All
PCR products were digested with XhoI and XbaI, gel puriﬁed and
individually inserted in pGFP-C3 vector (BD Bioscience, Mississauga,
ON) at the corresponding sites previously treatedwith the same restric-
tion enzymes. The plasmid pRc-CMV-UBC9 coding for UBC9 was real-
ized using the complete UBC9 mouse coding sequence ampliﬁed with
forward primer 5′-CACAAGCTTATGTCGGGGATCGCCCTC-3′ and Ubc9
reverse primer 5′-GCTCTAGATTATGAGGGGGCAAACTTCTT-3′. The PCR
product was digested with HindIII and XbaI respectively, gel puriﬁed
and inserted into pRc-CMV vector (Invitrogen Life technology, Carlsbad,
CA) at the corresponding sites previously treatedwith the same restric-
tion enzymes. The plasmid-pcDNA3-N-MYC-ANXA1 coding for ANXA1ane fraction) were solubilized and separated by 2-DE. Protein spots were revealed by
munobloting procedure using the anti-SUMO-1 antibody (lower panels). Black and
ite) after castration (GDX), compared to controls and after DHT treatment. Numbered
ass spectrometry identiﬁcation procedure.
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using: Annexin 1 forward primer: 5′-CACGCGGCCGCTCATGGCAATGG
TATCAGAATTCCTC-3′; and ANXA1 reverse primer: 5′-GCTCTAGACTAG
TTTCCACCACACAGAGCCAC-3′. PCR products were digested with NotI
and XbaI, gel puriﬁed and inserted into pcDNA3-N-MYC at the corre-
sponding site to generate fusion protein bearing anN terminusMYC tag.
2.9. Site-directed mutagenesis
Mutagenesis was carried out by polymerase chain reaction (PCR).
The mutations were made in the plasmid template pcDNA3-N-MYC-Fig. 3. SUMOylation of ANXA1 in LNCaP cells. A) LNCaP cells were co-transfected with
MYC-ANXA1, Immunoblot (150 ug proteins) were realized using α-SUMO-1, α-GFP and α–
A1. B) Immunoprecipitation (IP) of SUMOylated ANXA1. LNCaP cells co-transfected with EGF
antibodies and protein G-Agarose beads. Proteins were separated on SDS-PAGE and immuno
exposure times of the same membrane. NT: non-transfected cells. Ig: immunoglobulins.ANXA1 using the GeneTailor™ Site-Directed Mutagenesis System
(Invitrogen Life technology, Carlsbad, CA) according to themanufacturer's
protocol. Base substitution mutagenic oligonucleotide overlapping
primers corresponding to position single mutants were performed
for MmANXA1 on K161R, K185R, K257R and Y21F.
2.10. Immunoprecipitation (IP)
Proteins (1 mg) in Laemmli sample buffer were diluted 10 fold
(50 mM Tris HCl pH 7.5, 1% NP-40, 0.25% sodium deoxycholate,
150 mM NaCl, 1 mM EDTA, 1 mM PMSF, tablet of protease inhibitorEGFP-SUMO-1GG or EGFP-SUMO-1Δ and M. musculus MYC-RanGAP1 or M. musculus
β-galactosidase. NT = LNCaP non-transfected cells. MYC-Anxa1S: Sumoylated annexin
P-SUMO-1GG andMYC-ANXA1. IPs (250 ug proteins) were done using α-MYC orα-GFP
blotted using the α-MYC or the α-GFP antibody. The separation line indicates different
Fig. 4. Site-directed mutagenesis of ANXA1. LNCaP cells were co-transfected with the
EGFP-SUMO-1Δ or EGFP-SUMO-1GG.and with the wild type construct or construct bear-
ing mutations (K257R, K161R, K185R) from predicted consensus SUMOylation sites in
the M. musculus (Mm) MYC-ANXA1 (MmA1) DA3 domain. Proteins (150 μg) prepared
in Laemmli buffer were separated by SDS-PAGE and transferred on PVDFmembrane. Im-
munoblot were realized using an α-MYC antibody. NT = non-transfected cells.
MYC-ANXA1S: SUMOylated annexin A1. Relative units were calculated from values of
the mutated and wild-type (control) 78 kDa MmA1-SUMO/ANXA1 ratios and expressed
as percent of control. Mean ± S.E. (n = 4), ***p ≤ 0.006. The separation line indicates
same exposure times from different pieces of gel. NT: non-transfected cells.
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cipitation (IP)). IPs were performed following a pre-clearing step
using protein G-Agarose (Roche Diagnostics Canada, Laval, QC), at
4 °C with constant agitation during 120 min using 2 μg of antibody
of interest: anti-GFP (Invitrogen Life technology, Carlsbad, CA),
anti-MYC (9E10) (Santa Cruz Biotechnology, Santa Cruz, CA). Protein
G-Agarose was added for an additional 30 min. Beads were
centrifuged (1 min, 12,000 g) and rinsed once in buffer A (50 mM
HEPES pH 7.4, 1% Triton X-100, 0.1% SDS) and three times in buffer
B (50 mM HEPES pH 7.4, 1% Triton X-100). Proteins were directly
eluted in Laemmli sample buffer, boiled for 5 min and then stored
at −20 °C prior to gel loading.
2.11. Molecular modeling
The ANXA1 model was built using the modeling software
MODELLER [33]. The model was analyzed by using Ramachandran
plot through PROCHECK [34]. The ANXA1 models show 98% amino
acids in favored region of Ramachandran plot.
The docking of SUMO 1 in ANXA1 was performed by using the
crystal 1WYW and the software Patchdock [35,36]. The latter is
based on shape complementarity principles. The parameters used
in this docking, clustering RMSD: 4 A complex and type: Protein–
protein. The pics were generated by PyMol (http://www.pymol.org/).
3. Results
3.1. Protein SUMOylation in prostate fractions
A large pool of free SUMO-1 peptides, responsive to androgens,
was previously observed in the mouse prostate [32], a tissue highly
specialized in protein secretion. Immunoblot analysis with an
anti-SUMO-1 antibody showed the presence in 1-DE gels of a coinci-
dent proﬁle of protein bands, whose SUMOylation responded to hor-
monal treatment (Fig. 1). Immunoblot analysis of 2-DE also showed
protein spots revealed with the anti-SUMO-1 antibody. Several new
spots appeared or had increased intensity following castration and
then returned to basal level following a single dose of DHT replacement
(Fig. 2). These spots were excised for identiﬁcation by mass spectrome-
try. 26 proteins were unambiguously identiﬁed and were classiﬁed in
the intracellular trafﬁcking, signal transduction, translation/RNA pro-
cessing, cytoskeleton, metabolism, protein folding and processing cate-
gories. Hence the results indicated that the SUMOylation of a number of
prostate membrane proteins was sensitive to the hormonal DHT treat-
ment. Among the identiﬁed proteins, were members of the annexin
family (spot 1, including ANXA2 and ANXA3). We chose to further
analyze ANXA1 and its regulation by SUMOylation because annexins
play an important role in the homeostasis of the prostate and several
studies have observed the dysfunction of annexins in prostate can-
cer [37,38].
3.2. SUMOylation of ANXA1 in cultured cells
To validate annexin SUMOylationwe used a human cell line derived
from a prostate carcinoma (LNCaP) [39]. Proteins from LNCaP cells tran-
siently transfectedwith GFP-SUMO-1GG and SUMO-1Δ, the conjugating
and conjugation deﬁcient forms of SUMO-1 respectively were exam-
ined. Large amounts of GFP-SUMO-1 were expressed concomitantly
with appearance of protein bands when the active form SUMO-1GG
was overexpressed (Fig. 3A, left panel). Protein SUMOylation was fur-
ther validated by co-transfecting the MYC-tagged protein RanGAP1 as
a positive control [40] (Fig. 3A). Co-transfections with M. musculus
MYC-ANXA1 revealed the presence of a major 78 kDa signal. The
78 kDa signal is compatible with the presence of a complex com-
posed of one GFP-SUMO-1 molecule (around 40 kDa) bound to
the MYC-ANXA1 (around 38 kDa). A weaker 90 kDa signal was alsoobserved in some experiments (Fig. 3A, right panel). To further conﬁrm
these results we immunoprecipitated the GFP and MYC tagged proteins
before immunoblot analysis. The results conﬁrmed robust SUMOylation
ofM. musculusMYC-ANXA1 (Fig. 3B).
3.3. Identiﬁcation of the ANXA1 SUMOylation sites
We next used a site-directed mutagenesis experimental approach
to identify the exact location of the SUMOylation sites on ANXA1.
SUMO consensus motifs were ﬁrst localized by in silico analysis.
K161R, K185R, K257R mutations located in the consensus SUMO
motif (ψKXE/D, respective SUMOplot™ scores: 0.91, 0.80 and 0.91)
of ANXA1 were tested. The results presented in Fig. 4 conﬁrmed the
presence of the 78 kDa signal. This complex is compatible with one
SUMO-1 molecule bound to the tagged ANXA1. The SUMOylation
signal was not signiﬁcantly affected by the K161R and K185R muta-
tions. It was however markedly decreased by the K257R mutation
(256-LKGD-259) (Fig. 4).
3.4. EGF increases ANXA1 SUMOylation
Several works have demonstrated that the N-terminal domain is
particularly important for ANXA function [2–5,7,41]. Phosphorylation
Fig. 5. Stimulation of ANXA1 SUMOylation by EGF. A) LNCaP cells were co-transfected with the EGFP-SUMO-1GG and the wild type construct or a construct bearing the Y21F
mutation in the N-terminal sequence ofM. musculus (Mm) MYC-ANXA1 (MmA1). Proteins (150 ug) were separated on SDS-PAGE and immunoblotted using the α-MYC antibody.
Relative units were calculated from values of the mutated and wild-type (control) 78 kDa ANXA1-SUMO/ANXA1 ratios and expressed as percent control. Mean ± S.E. (n = 4,
*p ≤ 0.02). B) LNCaP cells were co-transfected with the EGFP-SUMO-1GG and the wild type construct. Cells were cultivated in the presence or absence (two hours) of FBS and stim-
ulated with EGF for 15 min (15 ng/ml). Proteins (150 μg) prepared in the Laemmli buffer were separated by SDS-PAGE and transferred on PVDF membrane. Immunoblots were
realized using an α-MYC, α-EGFR or α-p-TYR antibody (170 kDa EGFR-P, pieces of the same membrane, representative of two independent experiments). NT = non-transfected
cells. MYC-ANXA1S: SUMOylated annexin A1.
1967D. Caron et al. / Cellular Signalling 25 (2013) 1962–1969of Y- (and S-) residues in the N-terminal region regulates its function
[1–3,6,12,42–45]. Indeed, it was shown that Y21 and S27 of ANXA1
are phosphorylated by protein tyrosine kinases and protein kinases
A and C [6,42,46]. Given the role of annexins phosphorylation we
next veriﬁed if an external signal (EGF) could regulate the SUMO-1
modiﬁcation process. First we found that the Y21F mutation in
ANXA1 decreased signiﬁcantly by 40% the SUMOylation signal of the
78 kDa complex (Fig. 5A). We also veriﬁed if ANXA1 SUMOylation is
affected after EGF stimulation. The results indicated that LNCaP cells
overexpressing ANXA1 and SUMO-1 cultivated in the absence of
serum for 2 h displayed an approximately 50% lower ANXA1
SUMOylation signal. In addition, following a 15 minute EGF stimula-
tion, EGFR autophosphorylation increased markedly coincident withFig. 6. Ribbon diagram of the three-dimensional structure of SUMO-1 (green) docked
with Mm ANXA1 (blue). SUMO-1 docked with Lys257. Note that Leu256 is part of
the DA3 SUMO consensus motif (LKGD). Several overlapping modulation sites impli-
cated this region, as Ca2+ binding, nuclear export signal and polyubiquitination.an increased SUMOylation signal (Fig. 5B). These data indicate that
phosphorylation of tyrosine residue in the N-terminal region of
ANXA1 inﬂuences the SUMOylation intensity.
3.5. Molecular modeling and docking
To further understand the molecular signiﬁcance of the experi-
mental results of the K257R mutation on the SUMOylation of
ANXA1, we constructed a M. musculus model from the Sus scrofa
ANXA1 crystallized with and without Ca2+ (PDB code: 1MCX and
1HM6, respectively) [47] (Fig. 6). Human SUMO-1 (PDB code: 1WYW)
was docked into the modeled MnANXA1 at K257 (Fig. 6).
The Ca2+ binding site located in the DE loop of DA3, is composed of
D253, L256 and E261 (Fig. 6). It is interesting to note that K257 forms
hydrogen bondwith E261 in ANXA1 without Ca2+. This bond is broken
in structure with Ca2+. The SUMOylation of K257 can mask calcium
site of DE loop in DA3. In addition, there is a conserved leucine-rich
nuclear export signal (NES) upstream to K257 (LELK256GD; NetNes
Software) where L256 is part of the SUMO consensus motif. ASAview
[48] showed that Y21 situated in the N-terminal domain is buried,
leading to the hypothesis that without Ca2+ no phosphorylation of
Y21 is likely to occur [47].
4. Discussion
We found that ANXA1 was SUMOylated in prostate membrane
fractions and that this modiﬁcation was responsive to a hormonal
treatment. Previously reported SUMO targets involved in cancer
development are tumor suppressors such as p53 and the androgen
receptor [49]. The expression of ANXA1 was recently associated
with prostate cancer development and recurrence after androgen
deprivation therapy [14]. Cheng et al. [30] have suggested a role
for deSUMOylation in the development of prostate cancer. The
deSUMOylating enzyme SENP1 was found over-expressed over 2-fold
in human prostate cancer specimens [50]. This may explain in part the
association of the counteracting deSUMOylation process and prostate
cancer [30,31,51,52].
1968 D. Caron et al. / Cellular Signalling 25 (2013) 1962–1969Using in silico analysis and site-directed mutagenesis, we identiﬁed
K257 in ANXA1 as a major SUMOylable site. Of interest, the region
where K257 is localized contains several overlapping modulation
sites including a Ca2+ binding site, a nuclear export signal (NES), and
a polyubiquitination site [53]. Hirata et al. [54] and Shimoji et al. [53]
have demonstrated that SUMOylation and polyubiquitination of
ANXA1 are calcium-dependent in vitro. The Ca2+ binding site of the
DE loop of DA3 is composed of D253, L256 and E261 [47]. This later
forms a hydrogen bondwith K257, which is broken upon Ca2+ binding.
Therefore the SUMOylation of K257 canmask the calcium site of the DE
loop of DA3. The conformation of ANXA1 changes by Ca2+ binding in
DA3 domain followed by the release of the N-terminal domain [47].
Varticovski et al. [42] showed that Y21 and S27 of ANXA1 are phos-
phorylated by protein tyrosine kinases and protein kinases A/C, respec-
tively. Schlaepfer and Haigler [46] have reported that the equivalent of
Y28, S28 is phosphorylated by protein kinase C. Solito et al. [55]
demonstrated that the phosphorylated ANXA1 was translocated
to the cell membrane. The Y21F mutation led here to a decreased
SUMOylation of ANXA1 (Fig. 5A). On the contrary EGF increased
the SUMOylation signal (Fig. 5B). It was reported that phosphorylation
of Y21 in ANXA1 inhibited its ability to aggregate chromafﬁn granules
[2,3]. Y21 phosphorylation was also shown to be involved in the
docking of ANXA1 to the neck of invaginating vesicles inmulti vesicular
bodies (MVBs) [11,56]. ANXA1 SUMOylation may thus interfere with
the inward vesiculation process of MVBs and thus late events in
EGFR trafﬁcking downstream of the substrate Hrs and the ESCRT
machinery [6].
On the other hand, it was reported that SUMOylation plays an
important role in the transport between the nucleus and cytoplasm. In
ANXA1 there is a conserved nuclear exportation signal upstream to
K257 (LEL256KGD) where L256 is part of the SUMO consensus motif.
Rhee et al. [57] reported that the presence of ANXA1 to the nucleus is fa-
vored by EGF in A549 cells. The overlapping of SUMOylation site and the
putative NES region in ANXA1 suggest that SUMOylation could prevent
the binding of nuclear export factors to NES so that SUMO-1–ANXA1 is
retained in the nucleus [58]. In this regard, Kindsmüller et al. [59] have
shown that intranuclear targeting and nuclear export of the adenovirus
E1B-55K protein are regulated by SUMO-1 conjugation.
The fact that SUMOylation of K257 can also protect ANXA1 from
the polyubiquitination process and thus its proteasomal degradation
[60] emphasizes the idea that K257 is located in a hot spot tightly reg-
ulated through a cross-talk between the N-terminal and C-terminal
domains of ANXA1.
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